quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:02:46·127d
PRRelease
Athira Pharma Inc. logo

Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million

ATHA· Athira Pharma Inc.
Health Care
Original source

Companies

  • ATHA
    Athira Pharma Inc.
    Health Care

Recent analyst ratings

  • Sep 19UpdateMizuho$0.50
  • Sep 4UpdateRodman & Renshaw-
  • Sep 4UpdateBTIG Research-
  • Sep 4UpdateJMP Securities-
  • Aug 19UpdateRodman & Renshaw$22.00
  • Oct 17UpdateJMP Securities$20.00

Related

  • SEC97d
    Amendment: SEC Form SCHEDULE 13D/A filed by Athira Pharma Inc.
  • SEC104d
    Athira Pharma Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Other Events, Leadership Update, Financial Statements and Exhibits
  • PR105d
    Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker "LONA"
  • INSIDER108d
    CHIEF MEDICAL OFFICER San Martin Javier converted options into 4,667 shares and sold $11,311 worth of shares (1,644 units at $6.88), increasing direct ownership by 42% to 10,189 units (SEC Form 4)
  • INSIDER108d
    President and CEO Litton Mark James sold $17,792 worth of shares (2,586 units at $6.88) and converted options into 10,834 shares, increasing direct ownership by 25% to 40,828 units (SEC Form 4)
  • INSIDER108d
    Chief Financial Officer Renninger Robert was granted 1,000 shares, converted options into 1,236 shares and sold $2,043 worth of shares (297 units at $6.88), increasing direct ownership by 18% to 12,857 units (SEC Form 4)
  • INSIDER108d
    CHIEF SCIENTIFIC OFFICER Church Kevin was granted 1,000 shares, converted options into 3,667 shares and sold $6,027 worth of shares (876 units at $6.88), increasing direct ownership by 22% to 20,681 units (SEC Form 4)
  • INSIDER108d
    General Counsel and CCO Worthington Mark converted options into 3,667 shares and sold $6,027 worth of shares (876 units at $6.88), increasing direct ownership by 25% to 13,978 units (SEC Form 4)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022